FDA Advances GraftAssureDx Review, Requests Additional Info as iMDx Nears Authorization
IMDX has more than doubled off its 52-week low of $2.33 on light trading volume (0.3× avg).
Summary
iMDx reported Q2 results and a significant regulatory update: the FDA completed its current review phase of GraftAssureDx in late July and requested additional information, which the company views as routine and a sign of being in later stages. This is the first kitted dd-cfDNA assay submitted for FDA authorization, and the agency's swift engagement is encouraging. The update follows favorable Medicare coverage expansion and positive head-to-head data published in June, strengthening the commercial case. Bio-Rad, a strategic investor, expressed confidence in the partnership. The company also noted expanded interest from major U.S. reference labs, bolstered by reimbursement clarity and clinical data. With a market cap around $154M, FDA authorization would be transformative, enabling in-house transplant monitoring and potentially disrupting the send-out testing model. Next catalyst: FDA decision timeline remains uncertain but progress suggests a resolution in coming quarters.
At the time of this announcement, IMDX was trading at $4.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $154M. The 52-week trading range was $2.33 to $8.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.